Advertisement
05/12/2020

Fresenius Kabi debuts generic Mycamine

Sandra Levy
Senior Editor
Sandra Levy profile picture

Fresenius Kabi is offering micafungin for injection in dosage strengths of 50 mg and 100 mg.

The product, which is available in a 10 ml vial, is the first generic of Astellas Pharma's Mycamine.

“We’re pleased to offer the first micafungin generic in the United States, expanding our anti-infective portfolio, and increasing supply of this much-needed medication. Fresenius Kabi is committed to providing products that enable clinicians to deliver high-quality, cost-effective therapies,” said John Ducker, president and CEO of Fresenius Kabi USA.

Micafungin for injection is an echinocandin indicated in adult and pediatric patients for:

  • Treatment of candidemia, acute disseminated candidiasis, candida peritonitis and abscesses in adult and pediatric patients 4 months of age and older;
  • Treatment of candidemia, acute disseminated candidiasis, candida peritonitis and abscesses without meningoencephalitis and/or ocular dissemination in pediatric patients younger than 4 months of age;
  • Treatment of esophageal candidiasis in adult and pediatric patients 4 months of age and older; and 
  • Prophylaxis of candida infections in adult and pediatric patients 4 months of age and older undergoing Hematopoietic Stem Cell Transplantation.
Advertisement
Advertisement